Report Overview
Nucleic acid drugs, also known as nucleic acid-based therapeutics, are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes.
The global Nucleic Acid and Oligonucleotide Drugs market size was estimated at USD 12490 million in 2023 and is projected to reach USD 17320.93 million by 2032, exhibiting a CAGR of 3.70% during the forecast period.
North America Nucleic Acid and Oligonucleotide Drugs market size was estimated at USD 3464.24 million in 2023, at a CAGR of 3.17% during the forecast period of 2025 through 2032.
This report provides a deep insight into the global Nucleic Acid and Oligonucleotide Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Nucleic Acid and Oligonucleotide Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Nucleic Acid and Oligonucleotide Drugs market in any manner.
Global Nucleic Acid and Oligonucleotide Drugs Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna
Market Segmentation (by Type)
Antisense Oligonucleotides (ASO)
siRNA
mRNA
Market Segmentation (by Application)
Neuromuscular Diseases
hATTR
COVID-19
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Nucleic Acid and Oligonucleotide Drugs Market
Overview of the regional outlook of the Nucleic Acid and Oligonucleotide Drugs Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Nucleic Acid and Oligonucleotide Drugs
1.2 Key Market Segments
1.2.1 Nucleic Acid and Oligonucleotide Drugs Segment by Type
1.2.2 Nucleic Acid and Oligonucleotide Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Nucleic Acid and Oligonucleotide Drugs Market Overview
2.1 Global Market Overview
2.1.1 Global Nucleic Acid and Oligonucleotide Drugs Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Nucleic Acid and Oligonucleotide Drugs Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Nucleic Acid and Oligonucleotide Drugs Market Competitive Landscape
3.1 Global Nucleic Acid and Oligonucleotide Drugs Sales by Manufacturers (2019-2025)
3.2 Global Nucleic Acid and Oligonucleotide Drugs Revenue Market Share by Manufacturers (2019-2025)
3.3 Nucleic Acid and Oligonucleotide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Nucleic Acid and Oligonucleotide Drugs Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Nucleic Acid and Oligonucleotide Drugs Sales Sites, Area Served, Product Type
3.6 Nucleic Acid and Oligonucleotide Drugs Market Competitive Situation and Trends
3.6.1 Nucleic Acid and Oligonucleotide Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest Nucleic Acid and Oligonucleotide Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Nucleic Acid and Oligonucleotide Drugs Industry Chain Analysis
4.1 Nucleic Acid and Oligonucleotide Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Nucleic Acid and Oligonucleotide Drugs Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Nucleic Acid and Oligonucleotide Drugs Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Type (2019-2025)
6.3 Global Nucleic Acid and Oligonucleotide Drugs Market Size Market Share by Type (2019-2025)
6.4 Global Nucleic Acid and Oligonucleotide Drugs Price by Type (2019-2025)
7 Nucleic Acid and Oligonucleotide Drugs Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Nucleic Acid and Oligonucleotide Drugs Market Sales by Application (2019-2025)
7.3 Global Nucleic Acid and Oligonucleotide Drugs Market Size (M USD) by Application (2019-2025)
7.4 Global Nucleic Acid and Oligonucleotide Drugs Sales Growth Rate by Application (2019-2025)
8 Nucleic Acid and Oligonucleotide Drugs Market Consumption by Region
8.1 Global Nucleic Acid and Oligonucleotide Drugs Sales by Region
8.1.1 Global Nucleic Acid and Oligonucleotide Drugs Sales by Region
8.1.2 Global Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Region
8.2 North America
8.2.1 North America Nucleic Acid and Oligonucleotide Drugs Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Nucleic Acid and Oligonucleotide Drugs Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Nucleic Acid and Oligonucleotide Drugs Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Nucleic Acid and Oligonucleotide Drugs Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Nucleic Acid and Oligonucleotide Drugs Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Nucleic Acid and Oligonucleotide Drugs Market Production by Region
9.1 Global Production of Nucleic Acid and Oligonucleotide Drugs by Region (2019-2025)
9.2 Global Nucleic Acid and Oligonucleotide Drugs Revenue Market Share by Region (2019-2025)
9.3 Global Nucleic Acid and Oligonucleotide Drugs Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Nucleic Acid and Oligonucleotide Drugs Production
9.4.1 North America Nucleic Acid and Oligonucleotide Drugs Production Growth Rate (2019-2025)
9.4.2 North America Nucleic Acid and Oligonucleotide Drugs Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Nucleic Acid and Oligonucleotide Drugs Production
9.5.1 Europe Nucleic Acid and Oligonucleotide Drugs Production Growth Rate (2019-2025)
9.5.2 Europe Nucleic Acid and Oligonucleotide Drugs Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Nucleic Acid and Oligonucleotide Drugs Production (2019-2025)
9.6.1 Japan Nucleic Acid and Oligonucleotide Drugs Production Growth Rate (2019-2025)
9.6.2 Japan Nucleic Acid and Oligonucleotide Drugs Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Nucleic Acid and Oligonucleotide Drugs Production (2019-2025)
9.7.1 China Nucleic Acid and Oligonucleotide Drugs Production Growth Rate (2019-2025)
9.7.2 China Nucleic Acid and Oligonucleotide Drugs Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 Sarepta Therapeutics
10.1.1 Sarepta Therapeutics Nucleic Acid and Oligonucleotide Drugs Basic Information
10.1.2 Sarepta Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Overview
10.1.3 Sarepta Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.1.4 Sarepta Therapeutics Business Overview
10.1.5 Sarepta Therapeutics Nucleic Acid and Oligonucleotide Drugs SWOT Analysis
10.1.6 Sarepta Therapeutics Recent Developments
10.2 Ionis Pharmaceuticals
10.2.1 Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Basic Information
10.2.2 Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Product Overview
10.2.3 Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.2.4 Ionis Pharmaceuticals Business Overview
10.2.5 Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs SWOT Analysis
10.2.6 Ionis Pharmaceuticals Recent Developments
10.3 Alnylam
10.3.1 Alnylam Nucleic Acid and Oligonucleotide Drugs Basic Information
10.3.2 Alnylam Nucleic Acid and Oligonucleotide Drugs Product Overview
10.3.3 Alnylam Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.3.4 Alnylam Nucleic Acid and Oligonucleotide Drugs SWOT Analysis
10.3.5 Alnylam Business Overview
10.3.6 Alnylam Recent Developments
10.4 Biogen
10.4.1 Biogen Nucleic Acid and Oligonucleotide Drugs Basic Information
10.4.2 Biogen Nucleic Acid and Oligonucleotide Drugs Product Overview
10.4.3 Biogen Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.4.4 Biogen Business Overview
10.4.5 Biogen Recent Developments
10.5 Nippon Shinyaku
10.5.1 Nippon Shinyaku Nucleic Acid and Oligonucleotide Drugs Basic Information
10.5.2 Nippon Shinyaku Nucleic Acid and Oligonucleotide Drugs Product Overview
10.5.3 Nippon Shinyaku Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.5.4 Nippon Shinyaku Business Overview
10.5.5 Nippon Shinyaku Recent Developments
10.6 Sobi
10.6.1 Sobi Nucleic Acid and Oligonucleotide Drugs Basic Information
10.6.2 Sobi Nucleic Acid and Oligonucleotide Drugs Product Overview
10.6.3 Sobi Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.6.4 Sobi Business Overview
10.6.5 Sobi Recent Developments
10.7 Novartis
10.7.1 Novartis Nucleic Acid and Oligonucleotide Drugs Basic Information
10.7.2 Novartis Nucleic Acid and Oligonucleotide Drugs Product Overview
10.7.3 Novartis Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.7.4 Novartis Business Overview
10.7.5 Novartis Recent Developments
10.8 BioNTech
10.8.1 BioNTech Nucleic Acid and Oligonucleotide Drugs Basic Information
10.8.2 BioNTech Nucleic Acid and Oligonucleotide Drugs Product Overview
10.8.3 BioNTech Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.8.4 BioNTech Business Overview
10.8.5 BioNTech Recent Developments
10.9 Pfizer
10.9.1 Pfizer Nucleic Acid and Oligonucleotide Drugs Basic Information
10.9.2 Pfizer Nucleic Acid and Oligonucleotide Drugs Product Overview
10.9.3 Pfizer Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.9.4 Pfizer Business Overview
10.9.5 Pfizer Recent Developments
10.10 Moderna Therapeutics
10.10.1 Moderna Therapeutics Nucleic Acid and Oligonucleotide Drugs Basic Information
10.10.2 Moderna Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Overview
10.10.3 Moderna Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.10.4 Moderna Therapeutics Business Overview
10.10.5 Moderna Therapeutics Recent Developments
10.11 Jazz Pharmaceuticals
10.11.1 Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Basic Information
10.11.2 Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Product Overview
10.11.3 Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.11.4 Jazz Pharmaceuticals Business Overview
10.11.5 Jazz Pharmaceuticals Recent Developments
10.12 CureVac
10.12.1 CureVac Nucleic Acid and Oligonucleotide Drugs Basic Information
10.12.2 CureVac Nucleic Acid and Oligonucleotide Drugs Product Overview
10.12.3 CureVac Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.12.4 CureVac Business Overview
10.12.5 CureVac Recent Developments
10.13 Regulus Therapeutics
10.13.1 Regulus Therapeutics Nucleic Acid and Oligonucleotide Drugs Basic Information
10.13.2 Regulus Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Overview
10.13.3 Regulus Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.13.4 Regulus Therapeutics Business Overview
10.13.5 Regulus Therapeutics Recent Developments
10.14 ProQR
10.14.1 ProQR Nucleic Acid and Oligonucleotide Drugs Basic Information
10.14.2 ProQR Nucleic Acid and Oligonucleotide Drugs Product Overview
10.14.3 ProQR Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.14.4 ProQR Business Overview
10.14.5 ProQR Recent Developments
10.15 Secarna
10.15.1 Secarna Nucleic Acid and Oligonucleotide Drugs Basic Information
10.15.2 Secarna Nucleic Acid and Oligonucleotide Drugs Product Overview
10.15.3 Secarna Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.15.4 Secarna Business Overview
10.15.5 Secarna Recent Developments
10.16 MiNA Therapeutics
10.16.1 MiNA Therapeutics Nucleic Acid and Oligonucleotide Drugs Basic Information
10.16.2 MiNA Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Overview
10.16.3 MiNA Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.16.4 MiNA Therapeutics Business Overview
10.16.5 MiNA Therapeutics Recent Developments
10.17 Sylentis
10.17.1 Sylentis Nucleic Acid and Oligonucleotide Drugs Basic Information
10.17.2 Sylentis Nucleic Acid and Oligonucleotide Drugs Product Overview
10.17.3 Sylentis Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.17.4 Sylentis Business Overview
10.17.5 Sylentis Recent Developments
10.18 Arrowhead
10.18.1 Arrowhead Nucleic Acid and Oligonucleotide Drugs Basic Information
10.18.2 Arrowhead Nucleic Acid and Oligonucleotide Drugs Product Overview
10.18.3 Arrowhead Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.18.4 Arrowhead Business Overview
10.18.5 Arrowhead Recent Developments
10.19 Silence Therapeutics
10.19.1 Silence Therapeutics Nucleic Acid and Oligonucleotide Drugs Basic Information
10.19.2 Silence Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Overview
10.19.3 Silence Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.19.4 Silence Therapeutics Business Overview
10.19.5 Silence Therapeutics Recent Developments
10.20 Dicerna
10.20.1 Dicerna Nucleic Acid and Oligonucleotide Drugs Basic Information
10.20.2 Dicerna Nucleic Acid and Oligonucleotide Drugs Product Overview
10.20.3 Dicerna Nucleic Acid and Oligonucleotide Drugs Product Market Performance
10.20.4 Dicerna Business Overview
10.20.5 Dicerna Recent Developments
11 Nucleic Acid and Oligonucleotide Drugs Market Forecast by Region
11.1 Global Nucleic Acid and Oligonucleotide Drugs Market Size Forecast
11.2 Global Nucleic Acid and Oligonucleotide Drugs Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Country
11.2.3 Asia Pacific Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Region
11.2.4 South America Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Nucleic Acid and Oligonucleotide Drugs by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Nucleic Acid and Oligonucleotide Drugs Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Nucleic Acid and Oligonucleotide Drugs by Type (2025-2032)
12.1.2 Global Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Nucleic Acid and Oligonucleotide Drugs by Type (2025-2032)
12.2 Global Nucleic Acid and Oligonucleotide Drugs Market Forecast by Application (2025-2032)
12.2.1 Global Nucleic Acid and Oligonucleotide Drugs Sales (K MT) Forecast by Application
12.2.2 Global Nucleic Acid and Oligonucleotide Drugs Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Nucleic Acid and Oligonucleotide Drugs Market Size Comparison by Region (M USD)
Table 5. Global Nucleic Acid and Oligonucleotide Drugs Sales (K MT) by Manufacturers (2019-2025)
Table 6. Global Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Manufacturers (2019-2025)
Table 7. Global Nucleic Acid and Oligonucleotide Drugs Revenue (M USD) by Manufacturers (2019-2025)
Table 8. Global Nucleic Acid and Oligonucleotide Drugs Revenue Share by Manufacturers (2019-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleic Acid and Oligonucleotide Drugs as of 2022)
Table 10. Global Market Nucleic Acid and Oligonucleotide Drugs Average Price (USD/MT) of Key Manufacturers (2019-2025)
Table 11. Manufacturers Nucleic Acid and Oligonucleotide Drugs Sales Sites and Area Served
Table 12. Manufacturers Nucleic Acid and Oligonucleotide Drugs Product Type
Table 13. Global Nucleic Acid and Oligonucleotide Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Nucleic Acid and Oligonucleotide Drugs
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Nucleic Acid and Oligonucleotide Drugs Market Challenges
Table 22. Global Nucleic Acid and Oligonucleotide Drugs Sales by Type (K MT)
Table 23. Global Nucleic Acid and Oligonucleotide Drugs Market Size by Type (M USD)
Table 24. Global Nucleic Acid and Oligonucleotide Drugs Sales (K MT) by Type (2019-2025)
Table 25. Global Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Type (2019-2025)
Table 26. Global Nucleic Acid and Oligonucleotide Drugs Market Size (M USD) by Type (2019-2025)
Table 27. Global Nucleic Acid and Oligonucleotide Drugs Market Size Share by Type (2019-2025)
Table 28. Global Nucleic Acid and Oligonucleotide Drugs Price (USD/MT) by Type (2019-2025)
Table 29. Global Nucleic Acid and Oligonucleotide Drugs Sales (K MT) by Application
Table 30. Global Nucleic Acid and Oligonucleotide Drugs Market Size by Application
Table 31. Global Nucleic Acid and Oligonucleotide Drugs Sales by Application (2019-2025) & (K MT)
Table 32. Global Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Application (2019-2025)
Table 33. Global Nucleic Acid and Oligonucleotide Drugs Sales by Application (2019-2025) & (M USD)
Table 34. Global Nucleic Acid and Oligonucleotide Drugs Market Share by Application (2019-2025)
Table 35. Global Nucleic Acid and Oligonucleotide Drugs Sales Growth Rate by Application (2019-2025)
Table 36. Global Nucleic Acid and Oligonucleotide Drugs Sales by Region (2019-2025) & (K MT)
Table 37. Global Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Region (2019-2025)
Table 38. North America Nucleic Acid and Oligonucleotide Drugs Sales by Country (2019-2025) & (K MT)
Table 39. Europe Nucleic Acid and Oligonucleotide Drugs Sales by Country (2019-2025) & (K MT)
Table 40. Asia Pacific Nucleic Acid and Oligonucleotide Drugs Sales by Region (2019-2025) & (K MT)
Table 41. South America Nucleic Acid and Oligonucleotide Drugs Sales by Country (2019-2025) & (K MT)
Table 42. Middle East and Africa Nucleic Acid and Oligonucleotide Drugs Sales by Region (2019-2025) & (K MT)
Table 43. Global Nucleic Acid and Oligonucleotide Drugs Production (K MT) by Region (2019-2025)
Table 44. Global Nucleic Acid and Oligonucleotide Drugs Revenue (US$ Million) by Region (2019-2025)
Table 45. Global Nucleic Acid and Oligonucleotide Drugs Revenue Market Share by Region (2019-2025)
Table 46. Global Nucleic Acid and Oligonucleotide Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 47. North America Nucleic Acid and Oligonucleotide Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 48. Europe Nucleic Acid and Oligonucleotide Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 49. Japan Nucleic Acid and Oligonucleotide Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 50. China Nucleic Acid and Oligonucleotide Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 51. Sarepta Therapeutics Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 52. Sarepta Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 53. Sarepta Therapeutics Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 54. Sarepta Therapeutics Business Overview
Table 55. Sarepta Therapeutics Nucleic Acid and Oligonucleotide Drugs SWOT Analysis
Table 56. Sarepta Therapeutics Recent Developments
Table 57. Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 58. Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 59. Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 60. Ionis Pharmaceuticals Business Overview
Table 61. Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs SWOT Analysis
Table 62. Ionis Pharmaceuticals Recent Developments
Table 63. Alnylam Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 64. Alnylam Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 65. Alnylam Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 66. Alnylam Nucleic Acid and Oligonucleotide Drugs SWOT Analysis
Table 67. Alnylam Business Overview
Table 68. Alnylam Recent Developments
Table 69. Biogen Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 70. Biogen Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 71. Biogen Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 72. Biogen Business Overview
Table 73. Biogen Recent Developments
Table 74. Nippon Shinyaku Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 75. Nippon Shinyaku Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 76. Nippon Shinyaku Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 77. Nippon Shinyaku Business Overview
Table 78. Nippon Shinyaku Recent Developments
Table 79. Sobi Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 80. Sobi Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 81. Sobi Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 82. Sobi Business Overview
Table 83. Sobi Recent Developments
Table 84. Novartis Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 85. Novartis Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 86. Novartis Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 87. Novartis Business Overview
Table 88. Novartis Recent Developments
Table 89. BioNTech Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 90. BioNTech Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 91. BioNTech Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 92. BioNTech Business Overview
Table 93. BioNTech Recent Developments
Table 94. Pfizer Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 95. Pfizer Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 96. Pfizer Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 97. Pfizer Business Overview
Table 98. Pfizer Recent Developments
Table 99. Moderna Therapeutics Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 100. Moderna Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 101. Moderna Therapeutics Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 102. Moderna Therapeutics Business Overview
Table 103. Moderna Therapeutics Recent Developments
Table 104. Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 105. Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 106. Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 107. Jazz Pharmaceuticals Business Overview
Table 108. Jazz Pharmaceuticals Recent Developments
Table 109. CureVac Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 110. CureVac Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 111. CureVac Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 112. CureVac Business Overview
Table 113. CureVac Recent Developments
Table 114. Regulus Therapeutics Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 115. Regulus Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 116. Regulus Therapeutics Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 117. Regulus Therapeutics Business Overview
Table 118. Regulus Therapeutics Recent Developments
Table 119. ProQR Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 120. ProQR Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 121. ProQR Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 122. ProQR Business Overview
Table 123. ProQR Recent Developments
Table 124. Secarna Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 125. Secarna Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 126. Secarna Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 127. Secarna Business Overview
Table 128. Secarna Recent Developments
Table 129. MiNA Therapeutics Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 130. MiNA Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 131. MiNA Therapeutics Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 132. MiNA Therapeutics Business Overview
Table 133. MiNA Therapeutics Recent Developments
Table 134. Sylentis Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 135. Sylentis Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 136. Sylentis Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 137. Sylentis Business Overview
Table 138. Sylentis Recent Developments
Table 139. Arrowhead Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 140. Arrowhead Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 141. Arrowhead Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 142. Arrowhead Business Overview
Table 143. Arrowhead Recent Developments
Table 144. Silence Therapeutics Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 145. Silence Therapeutics Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 146. Silence Therapeutics Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 147. Silence Therapeutics Business Overview
Table 148. Silence Therapeutics Recent Developments
Table 149. Dicerna Nucleic Acid and Oligonucleotide Drugs Basic Information
Table 150. Dicerna Nucleic Acid and Oligonucleotide Drugs Product Overview
Table 151. Dicerna Nucleic Acid and Oligonucleotide Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 152. Dicerna Business Overview
Table 153. Dicerna Recent Developments
Table 154. Global Nucleic Acid and Oligonucleotide Drugs Sales Forecast by Region (2025-2032) & (K MT)
Table 155. Global Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Region (2025-2032) & (M USD)
Table 156. North America Nucleic Acid and Oligonucleotide Drugs Sales Forecast by Country (2025-2032) & (K MT)
Table 157. North America Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Country (2025-2032) & (M USD)
Table 158. Europe Nucleic Acid and Oligonucleotide Drugs Sales Forecast by Country (2025-2032) & (K MT)
Table 159. Europe Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Country (2025-2032) & (M USD)
Table 160. Asia Pacific Nucleic Acid and Oligonucleotide Drugs Sales Forecast by Region (2025-2032) & (K MT)
Table 161. Asia Pacific Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Region (2025-2032) & (M USD)
Table 162. South America Nucleic Acid and Oligonucleotide Drugs Sales Forecast by Country (2025-2032) & (K MT)
Table 163. South America Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Country (2025-2032) & (M USD)
Table 164. Middle East and Africa Nucleic Acid and Oligonucleotide Drugs Consumption Forecast by Country (2025-2032) & (Units)
Table 165. Middle East and Africa Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Country (2025-2032) & (M USD)
Table 166. Global Nucleic Acid and Oligonucleotide Drugs Sales Forecast by Type (2025-2032) & (K MT)
Table 167. Global Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Type (2025-2032) & (M USD)
Table 168. Global Nucleic Acid and Oligonucleotide Drugs Price Forecast by Type (2025-2032) & (USD/MT)
Table 169. Global Nucleic Acid and Oligonucleotide Drugs Sales (K MT) Forecast by Application (2025-2032)
Table 170. Global Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Application (2025-2032) & (M USD)
List of Figures
Figure 1. Product Picture of Nucleic Acid and Oligonucleotide Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Nucleic Acid and Oligonucleotide Drugs Market Size (M USD), 2019-2032
Figure 5. Global Nucleic Acid and Oligonucleotide Drugs Market Size (M USD) (2019-2032)
Figure 6. Global Nucleic Acid and Oligonucleotide Drugs Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Nucleic Acid and Oligonucleotide Drugs Market Size by Country (M USD)
Figure 11. Nucleic Acid and Oligonucleotide Drugs Sales Share by Manufacturers in 2023
Figure 12. Global Nucleic Acid and Oligonucleotide Drugs Revenue Share by Manufacturers in 2023
Figure 13. Nucleic Acid and Oligonucleotide Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Nucleic Acid and Oligonucleotide Drugs Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Nucleic Acid and Oligonucleotide Drugs Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Nucleic Acid and Oligonucleotide Drugs Market Share by Type
Figure 18. Sales Market Share of Nucleic Acid and Oligonucleotide Drugs by Type (2019-2025)
Figure 19. Sales Market Share of Nucleic Acid and Oligonucleotide Drugs by Type in 2023
Figure 20. Market Size Share of Nucleic Acid and Oligonucleotide Drugs by Type (2019-2025)
Figure 21. Market Size Market Share of Nucleic Acid and Oligonucleotide Drugs by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Nucleic Acid and Oligonucleotide Drugs Market Share by Application
Figure 24. Global Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Application (2019-2025)
Figure 25. Global Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Application in 2023
Figure 26. Global Nucleic Acid and Oligonucleotide Drugs Market Share by Application (2019-2025)
Figure 27. Global Nucleic Acid and Oligonucleotide Drugs Market Share by Application in 2023
Figure 28. Global Nucleic Acid and Oligonucleotide Drugs Sales Growth Rate by Application (2019-2025)
Figure 29. Global Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Region (2019-2025)
Figure 30. North America Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 31. North America Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Country in 2023
Figure 32. U.S. Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 33. Canada Nucleic Acid and Oligonucleotide Drugs Sales (K MT) and Growth Rate (2019-2025)
Figure 34. Mexico Nucleic Acid and Oligonucleotide Drugs Sales (Units) and Growth Rate (2019-2025)
Figure 35. Europe Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 36. Europe Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Country in 2023
Figure 37. Germany Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 38. France Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 39. U.K. Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 40. Italy Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 41. Russia Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 42. Asia Pacific Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Region in 2023
Figure 44. China Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 45. Japan Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 46. South Korea Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 47. India Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 48. Southeast Asia Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 49. South America Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (K MT)
Figure 50. South America Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Country in 2023
Figure 51. Brazil Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 52. Argentina Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 53. Columbia Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 54. Middle East and Africa Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Nucleic Acid and Oligonucleotide Drugs Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 57. UAE Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 58. Egypt Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 59. Nigeria Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 60. South Africa Nucleic Acid and Oligonucleotide Drugs Sales and Growth Rate (2019-2025) & (K MT)
Figure 61. Global Nucleic Acid and Oligonucleotide Drugs Production Market Share by Region (2019-2025)
Figure 62. North America Nucleic Acid and Oligonucleotide Drugs Production (K MT) Growth Rate (2019-2025)
Figure 63. Europe Nucleic Acid and Oligonucleotide Drugs Production (K MT) Growth Rate (2019-2025)
Figure 64. Japan Nucleic Acid and Oligonucleotide Drugs Production (K MT) Growth Rate (2019-2025)
Figure 65. China Nucleic Acid and Oligonucleotide Drugs Production (K MT) Growth Rate (2019-2025)
Figure 66. Global Nucleic Acid and Oligonucleotide Drugs Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Nucleic Acid and Oligonucleotide Drugs Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Nucleic Acid and Oligonucleotide Drugs Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Nucleic Acid and Oligonucleotide Drugs Market Share Forecast by Type (2025-2032)
Figure 70. Global Nucleic Acid and Oligonucleotide Drugs Sales Forecast by Application (2025-2032)
Figure 71. Global Nucleic Acid and Oligonucleotide Drugs Market Share Forecast by Application (2025-2032)
